{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:18:51Z","timestamp":1794745131456,"version":"4.9.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biopha.2026.119934","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:45:08Z","timestamp":1789555508000},"page":"119934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Non-clinical safety evaluation of coenzyme I (NAD\u207a): A GLP-compliant systematic study"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0668-508X","authenticated-orcid":false,"given":"Jingliang","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"519","key":"10.1016\/j.biopha.2026.119934_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1098\/rspb.1906.0029","article-title":"The alcoholic ferment of yeast-juice","volume":"77","author":"Harden","year":"1906","journal-title":"Proc. R. Soc. Lond. B"},{"issue":"1","key":"10.1016\/j.biopha.2026.119934_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cmet.2015.05.023","article-title":"NAD\u207a metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus","volume":"22","author":"Cant\u00f3","year":"2015","journal-title":"Cell. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2026.119934_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41392-020-00354-w","article-title":"NAD\u207a metabolism, stemness, the immune response, and cancer","volume":"6","author":"Navas","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"6265","key":"10.1016\/j.biopha.2026.119934_bib4","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aac4854","article-title":"NAD\u207a in aging, metabolism, and neurodegeneration","volume":"350","author":"Verdin","year":"2015","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.biopha.2026.119934_bib5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tcb.2014.04.002","article-title":"NAD\u207a and sirtuins in aging and disease","volume":"24","author":"Imai","year":"2014","journal-title":"Trends Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119934_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2026.103305","article-title":"NAD\u207a circuits in aging, tissue repair and fibrosis","volume":"122","author":"Izadpanah","year":"2026","journal-title":"Ageing Res. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2026.119934_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrneph.2017.5","article-title":"Role of NAD\u207a and mitochondrial sirtuins in cardiac and renal diseases","volume":"13","author":"Hershberger","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119934_bib8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.cmet.2016.05.022","article-title":"Why NAD\u207a declines during aging: it\u2019s destroyed","volume":"23","author":"Schultz","year":"2016","journal-title":"Cell. Metab."},{"issue":"7","key":"10.1016\/j.biopha.2026.119934_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042357","article-title":"Age-associated changes in oxidative stress and NAD\u207a metabolism in human tissue","volume":"7","author":"Massudi","year":"2012","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119934_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2026.104343","article-title":"Dynamics of blood NAD and glutathione in health, disease, aging, and under NAD\u207a-booster treatment","volume":"96","author":"Euro","year":"2026","journal-title":"Redox Biol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119934_bib11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/CIRCULATIONAHA.116.022495","article-title":"Normalization of NAD\u207a redox balance as a therapy for heart failure","volume":"134","author":"Lee","year":"2016","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.biopha.2026.119934_bib12","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1161\/CIRCULATIONAHA.116.026099","article-title":"Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy","volume":"137","author":"Diguet","year":"2018","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.biopha.2026.119934_bib13","first-page":"3342","article-title":"Exogenous NAD\u207a administration significantly protects against myocardial ischemia\/reperfusion injury in rat model","volume":"8","author":"Zhang","year":"2016","journal-title":"Am. J. Transl. Res."},{"issue":"12","key":"10.1016\/j.biopha.2026.119934_bib14","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3390\/biom14121556","article-title":"Pathobiochemistry of aging and neurodegeneration: deregulation of NAD\u207a metabolism in brain cells","volume":"14","author":"Kolotyeva","year":"2024","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.biopha.2026.119934_bib15","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.cmet.2022.02.001","article-title":"The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson\u2019s disease","volume":"34","author":"Brakedal","year":"2022","journal-title":"Cell. Metab."},{"key":"10.1016\/j.biopha.2026.119934_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12868-025-00937-9","article-title":"A systematic review of the therapeutic potential of nicotinamide adenine dinucleotide precursors for cognitive diseases in preclinical rodent models","volume":"26","author":"Qader","year":"2025","journal-title":"BMC Neurosci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119934_bib17","first-page":"148","article-title":"Chinese geriatric expert consensus on anti-aging drug intervention research","volume":"43","author":"Liu","year":"2024","journal-title":"Chin. J. Geriatr."},{"issue":"4","key":"10.1016\/j.biopha.2026.119934_bib18","doi-asserted-by":"crossref","first-page":"E417","DOI":"10.1152\/ajpendo.00242.2023","article-title":"Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review","volume":"326","author":"Gindri","year":"2024","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.biopha.2026.119934_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.31083\/j.rcm2508297","article-title":"Effects of nicotinamide adenine dinucleotide on older patients with heart failure","volume":"25","author":"Pei","year":"2024","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2026.119934_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40256-025-00764-7","article-title":"Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: a randomized, placebo-controlled trial","volume":"26","author":"Yu","year":"2026","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.biopha.2026.119934_bib21","unstructured":"M.N. Elshabrawi, K.A. Hamzah, Effects of exogenous nicotinamide adenine dinucleotide (NAD\u207a) and nicotinamide riboside supplementation in adults with symptomatic heart failure: a systematic review and meta-analysis of randomized controlled trials, PROSPERO CRD420251251462 (2025). https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251251462."},{"key":"10.1016\/j.biopha.2026.119934_bib22","unstructured":"U.S. Food and Drug Administration, Summary minutes of the Pharmacy Compounding Advisory Committee meeting, May 8-9, 2017, FDA, Silver Spring, MD (2017). https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/pharmacy-compounding-advisory-committee-meeting."},{"key":"10.1016\/j.biopha.2026.119934_bib23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12929-016-0267-y","article-title":"Effects of exogenous nicotinamide adenine dinucleotide (NAD\u207a) in the rat heart are mediated by P2 purine receptors","volume":"23","author":"Kuzmin","year":"2016","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.biopha.2026.119934_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2023.104677","article-title":"Damage-induced NAD release activates intestinal CD4\u207a and CD8\u207a T cell via P2X7R signaling","volume":"385","author":"Bu","year":"2023","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.biopha.2026.119934_bib25","unstructured":"National Medical Products Administration, Technical guidelines for irritation, sensitization and hemolysis studies of drugs, NMPA, Beijing (2014). https:\/\/www.nmpa.gov.cn\/directory\/web\/nmpa\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20140513120001448.html (accessed on 2024-06-01)."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:55:18Z","timestamp":1794743718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":25,"alternative-id":["S0753332226009704"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119934","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-clinical safety evaluation of coenzyme I (NAD\u207a): A GLP-compliant systematic study","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119934"}}